文献速递炎症性肠病

系统综述与荟萃分析:溃疡性结肠炎诱导和维持试验中内镜与组织学安慰剂率

Systematic review with meta-analysis: endoscopic and histologic placebo rates in induction and maintenance trials of ulcerative colitis.
PubMed 文献 · Aliment Pharmacol Ther · 2018-04-25

该系统综述与荟萃分析检索了MEDLINE、EMBASE和Cochrane图书馆至2017年3月的溃疡性结肠炎安慰剂对照试验,纳入56项诱导试验(安慰剂n=4171)和8项维持试验(安慰剂n=1011),汇总内镜和组织学安慰剂缓解率与应答率,并评估影响因素。结果显示诱导期内镜安慰剂缓解率23%、应答率35%,组织学安慰剂缓解率14%,异质性高;中心化内镜判读与较低内镜安慰剂缓解率相关。

要点

  • 诱导试验内镜安慰剂缓解率23%,应答率35%,组织学安慰剂缓解率14%。
  • 维持试验内镜安慰剂缓解率20%。
  • 中心化内镜判读与较低内镜安慰剂缓解率相关(16% vs 25%;OR=0.52)。

核心结论

  • 溃疡性结肠炎随机对照试验中安慰剂内镜和组织学率范围为14%至35%,但异质性高。
  • 结局标准化可能降低异质性,该领域需要结局标准化。

研究设计与样本

  • 系统综述与荟萃分析,检索MEDLINE、EMBASE和Cochrane图书馆从建库至2017年3月,纳入溃疡性结肠炎药物干预的安慰剂对照试验。
  • 共纳入56项诱导试验(安慰剂n=4171)和8项维持试验(安慰剂n=1011)。

主要发现

  • 诱导试验汇总安慰剂内镜缓解率为23%[95%CI 19-28%],内镜应答率为35%[95%CI 27-42%]。
  • 维持试验汇总安慰剂内镜缓解率为20%[95%CI 16-24%]。
  • 诱导试验汇总组织学安慰剂缓解率为14%[95%CI 8-22%]。
  • 所有结局均观察到高异质性(I² 56.2%-88.3%)。
  • 多因素荟萃回归显示中心化内镜判读与显著较低的内镜安慰剂缓解率相关(16% vs 25%;OR=0.52[95%CI 0.29-0.92],P=0.03)。

关键数值与推荐

  • 诱导期内镜安慰剂缓解率23%,内镜安慰剂应答率35%,组织学安慰剂缓解率14%。
  • 维持期内镜安慰剂缓解率20%。
  • 中心化内镜判读组内镜安慰剂缓解率16% vs 非中心化判读组25%(OR=0.52[95%CI 0.29-0.92],P=0.03)。
  • 皮质类固醇使用每增加10%,组织学安慰剂缓解的OR=1.17[95%CI 1.08-1.26],P<0.0001。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 所有结局均观察到高异质性(I² 56.2%-88.3%)。
  • 原文指出结局标准化可能降低异质性,该领域需要结局标准化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Regulatory requirements for claims of mucosal healing in ulcerative colitis (UC) will require demonstration of both endoscopic and histologic healing. Quantifying these rates is essential for future drug development. AIMS: To meta-analyse endoscopic and histologic placebo response and remission rates in UC randomised controlled trials (RCTs) and identify factors influencing these rates. METHODS: MEDLINE, EMBASE and the Cochrane Library were searched from inception to March 2017 for placebo-controlled trials of pharmacological interventions for UC. Endoscopic and histologic placebo rates were pooled by random effects. Mixed effects univariable and multivariable meta-regression was used to evaluate the influence of patient, intervention and trial-related study-level covariates on these rates. RESULTS: Fifty-six induction (placebo n = 4171) and 8 maintenance trials (placebo n = 1011) were included. Pooled placebo endoscopic remission and response rates for induction trials were 23% [95 confidence interval (CI) 19-28%] and 35% [95% CI 27-42%] respectively, and 20% [95% CI 16-24%] for maintenance of remission. The pooled histologic placebo remission rate was 14% [95% CI 8-22%] for induction trials. High heterogeneity was observed for all outcomes (I2 56.2%-88.3%). On multivariable meta-regression, central endoscopy reading was associated with significantly lower endoscopic placebo remission rates (16% vs 25%; OR = 0.52, [95% CI 0.29-0.92], P = 0.03). On univariable meta-regression, higher histologic placebo remission was associated with concomitant corticosteroids (OR = 1.17 [95% CI 1.08-1.26], P < 0.0001, per 10% increase in corticosteroid use). CONCLUSIONS: Placebo endoscopic and histologic rates range from 14% to 35% in UC RCTs but are highly heterogeneous. Outcome standardisation may reduce heterogeneity and is needed in this field.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Ma C, Guizzetti L, Panaccione R, et al. Systematic review with meta-analysis: endoscopic and histologic placebo rates in induction and maintenance trials of ulcerative colitis. Aliment Pharmacol Ther. 2018. PMID: 29696670. doi:10.1111/apt.14672

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。